Applying peptide and protein domain microarrays to epigenetic research
将肽和蛋白质域微阵列应用于表观遗传学研究
基本信息
- 批准号:7879014
- 负责人:
- 金额:$ 15.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-16 至 2011-06-30
- 项目状态:已结题
- 来源:
- 关键词:Amino Acid MotifsAntibodiesBindingBiologicalBiological AssayCell physiologyChemicalsChromatinCommunitiesDevelopmentDiseaseEpigenetic ProcessEpitopesEventGenerationsGoalsHealthHereditary DiseaseHistonesHomeostasisHumanImmunologic Deficiency SyndromesKnowledgeLeadLibrariesLinkLysineMacromolecular ComplexesMethodologyMethylationMicroarray AnalysisMinorityModelingModificationMolecularNamesNucleosomesOther GeneticsOutcomePHD FingerPathologic ProcessesPeptide LibraryPeptidesPhysiologicalPost-Translational Modification SitePost-Translational Protein ProcessingProtein ArrayProtein MicrochipsProteinsProteomeProteomicsReaderReadingResearchResearch PersonnelRoleSiteSoftware ToolsSystemTechnologyTechnology TransferTertiary Protein StructureTestingTherapeutic InterventionWorkbasechromatin modificationcombinatorialexperiencehistone modificationhuman diseaseinsightneoplasticnovelprogramspublic health relevancetooltumor progression
项目摘要
DESCRIPTION (provided by applicant): Dynamic post-translational modification (PTM) of histone proteins by chemical moieties such as acetyl-, methyl- and phospho- groups constitutes a key epigenetic mechanism that impacts on fundamental physiologic and pathologic processes. The proteins and domains that recognize distinct histone modification, named "readers", define the functional consequences of specific modifications by transducing molecular events at chromatin to biological outcomes. Thus, the elucidation of histone PTM readers is critical for understanding how chromatin dynamics contribute to epigenetic programs, and how disruption of chromatin homeostasis fundamentally impacts on the development and progression of cancers and other diseases. The long-term goal of this proposal is to develop novel protein array technologies for proteome-wide, high- throughput discovery and study of the writers and readers of epigenetic events. A general hypothesis to be tested in this proposal is that protein array technology will revolutionize the ability of epigenetic researchers to discover diverse readers for the broad spectrum of chromatin PTMs present in the human epigenome. The proposal focuses on protein methylation as a prototypical epigenetic event, with two specific Aims planned. In the first Aim, paradigms will be established to validate and utilize multiplex modified histone peptide microarrays for high-throughput binding assays in screens employing protein domain libraries (developed in Aim 2), purified chromatin-regulatory macromolecular complexes and anti-histone antibodies. In chip enzymatic assays will be performed to investigate the utility of peptide microarrays as a platform for identifying candidate histone-modifying activities. In the second Aim, protein domain microarrays containing a comprehensive library of chromatin-associated domains will be generated and characterized as high-throughput tools for epigenetic research. Multiple types of probes will be developed for testing these arrays, including dual modification peptide probes (developed in Aim 1) and modification specific nucleosomal probes. For both Aims, analytic tools and software will be developed and standardized to facilitate transfer of the technology developed in the proposal to the epigenetic community. The generation in this proposal of new proteomic technologies that allow for rapid and accurate discovery of chromatin PTM readers should prove highly valuable for elucidating how epigenetic events influence human health and disease.
PUBLIC HEALTH RELEVANCE: Epigenetic events at chromatin regulate diverse cellular functions critical for normal health. Dysregulation of the proteins that place and read epigenetic modifications are frequently linked to neoplastic disease, immunodeficiencies syndromes and numerous other genetic disorders. Our proposed studies should provide insight into how epigenetic dynamics functional at the molecular level, and potentially lead to the discovery of new epigenetic targets for therapeutic intervention in diverse human diseases.
描述(由申请人提供):化学部分(如乙酰基、甲基和磷酸基)对组蛋白的动态翻译后修饰(PTM)构成了影响基本生理和病理过程的关键表观遗传机制。识别不同组蛋白修饰的蛋白质和结构域,称为“阅读器”,通过将染色质上的分子事件转导为生物学结果来定义特定修饰的功能后果。因此,阐明组蛋白PTM阅读器对于理解染色质动力学如何有助于表观遗传程序以及染色质稳态的破坏如何从根本上影响癌症和其他疾病的发展和进展至关重要。该提案的长期目标是开发新的蛋白质阵列技术,用于蛋白质组范围内的高通量发现和表观遗传事件的作者和读者的研究。在这个提议中要测试的一般假设是,蛋白质阵列技术将彻底改变表观遗传学研究人员发现人类表观基因组中存在的广谱染色质PTM的不同读者的能力。该提案的重点是蛋白质甲基化作为一个典型的表观遗传事件,有两个具体的目标计划。在第一个目标中,将建立范式来验证和利用多重修饰的组蛋白肽微阵列,用于采用蛋白质结构域文库(在目标2中开发)、纯化的染色质调节大分子复合物和抗组蛋白抗体的筛选中的高通量结合测定。将进行芯片酶测定以研究肽微阵列作为鉴定候选组蛋白修饰活性的平台的效用。在第二个目标中,蛋白质结构域微阵列包含一个全面的库染色质相关的结构域将被生成和表征为高通量的工具,表观遗传学研究。将开发多种类型的探针用于测试这些阵列,包括双修饰肽探针(在目标1中开发)和修饰特异性核小体探针。对于这两个目标,将开发和标准化分析工具和软件,以促进将提案中开发的技术转让给表观遗传学界。这一新的蛋白质组学技术的产生,允许快速和准确地发现染色质PTM读者应该证明是非常有价值的阐明表观遗传事件如何影响人类健康和疾病的建议。
公共卫生相关性:染色质的表观遗传事件调节对正常健康至关重要的多种细胞功能。放置和读取表观遗传修饰的蛋白质的失调通常与肿瘤疾病、免疫缺陷综合征和许多其他遗传疾病有关。我们提出的研究应该提供深入了解表观遗传动力学如何在分子水平上发挥作用,并可能导致发现新的表观遗传靶点,用于治疗多种人类疾病。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Epigenome microarray platform for proteome-wide dissection of chromatin-signaling networks.
- DOI:10.1371/journal.pone.0006789
- 发表时间:2009-08-26
- 期刊:
- 影响因子:3.7
- 作者:Bua DJ;Kuo AJ;Cheung P;Liu CL;Migliori V;Espejo A;Casadio F;Bassi C;Amati B;Bedford MT;Guccione E;Gozani O
- 通讯作者:Gozani O
Borrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoforms.
Borrelidin 调节 VEGF 的选择性剪接,有利于抗血管生成亚型。
- DOI:10.1039/c0sc00297f
- 发表时间:2011
- 期刊:
- 影响因子:8.4
- 作者:Woolard,Jeanette;Vousden,William;Moss,StevenJ;Krishnakumar,Arjun;Gammons,MelissaVr;Nowak,DavidG;Dixon,Neil;Micklefield,Jason;Spannhoff,Astrid;Bedford,MarkT;Gregory,MatthewA;Martin,ChristineJ;Leadlay,PeterF;Zhang,MingQ;H
- 通讯作者:H
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARK T. BEDFORD其他文献
MARK T. BEDFORD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARK T. BEDFORD', 18)}}的其他基金
Mechanisms of action and therapeutic targeting of the CARM1-NFIB axis in small cell lung cancer
CARM1-NFIB 轴在小细胞肺癌中的作用机制和治疗靶向
- 批准号:
10657854 - 财政年份:2023
- 资助金额:
$ 15.33万 - 项目类别:
MD Anderson Science Park Summer Program in Cancer Research SPCR
MD 安德森科学园癌症研究 SPCR 暑期项目
- 批准号:
10472591 - 财政年份:2014
- 资助金额:
$ 15.33万 - 项目类别:
MD Anderson Science Park Summer Program in Cancer Research SPCR
MD 安德森科学园癌症研究 SPCR 暑期项目
- 批准号:
10685275 - 财政年份:2014
- 资助金额:
$ 15.33万 - 项目类别:
Epigenetic Programmers Targeted During Developmental Reprogramming
表观遗传程序员是发育重编程过程中的目标
- 批准号:
9068106 - 财政年份:2013
- 资助金额:
$ 15.33万 - 项目类别:
Epigenetic Programmers Targeted During Developmental Reprogramming
表观遗传程序员是发育重编程过程中的目标
- 批准号:
8726398 - 财政年份:2013
- 资助金额:
$ 15.33万 - 项目类别:
Epigenetic Programmers Targeted During Developmental Reprogramming
表观遗传程序员是发育重编程过程中的目标
- 批准号:
8584981 - 财政年份:2013
- 资助金额:
$ 15.33万 - 项目类别:
Epigenetic Programmers Targeted During Developmental Reprogramming
表观遗传程序员是发育重编程过程中的目标
- 批准号:
9412709 - 财政年份:2013
- 资助金额:
$ 15.33万 - 项目类别:
Identify small molecule inhibitors of methyl-dependent protein-protein interactio
鉴定甲基依赖性蛋白质-蛋白质相互作用的小分子抑制剂
- 批准号:
8011493 - 财政年份:2010
- 资助金额:
$ 15.33万 - 项目类别:
Identify small molecule inhibitors of methyl-dependent protein-protein interactio
鉴定甲基依赖性蛋白质-蛋白质相互作用的小分子抑制剂
- 批准号:
8089366 - 财政年份:2010
- 资助金额:
$ 15.33万 - 项目类别:
Applying peptide and protein domain microarrays to epigenetic research
将肽和蛋白质域微阵列应用于表观遗传学研究
- 批准号:
7688691 - 财政年份:2008
- 资助金额:
$ 15.33万 - 项目类别:
相似海外基金
Novel Carbohydrate-binding Antibodies to Human Glycans Using the Lamprey System
使用 Lamprey 系统开发针对人类聚糖的新型碳水化合物结合抗体
- 批准号:
10454419 - 财政年份:2021
- 资助金额:
$ 15.33万 - 项目类别:
Novel Carbohydrate-binding Antibodies to Human Glycans Using the Lamprey System
使用 Lamprey 系统开发针对人类聚糖的新型碳水化合物结合抗体
- 批准号:
10672258 - 财政年份:2021
- 资助金额:
$ 15.33万 - 项目类别:
Novel Carbohydrate-binding Antibodies to Human Glycans Using the Lamprey System
使用 Lamprey 系统开发针对人类聚糖的新型碳水化合物结合抗体
- 批准号:
10293635 - 财政年份:2021
- 资助金额:
$ 15.33万 - 项目类别:
Computational modelling and simulation of antibodies to enhance binding affinity of a potential Burkholderia pseudomallei therapeutic
抗体的计算模型和模拟,以增强潜在的鼻疽伯克霍尔德氏菌治疗剂的结合亲和力
- 批准号:
2750554 - 财政年份:2021
- 资助金额:
$ 15.33万 - 项目类别:
Studentship
Covalent binding Antibodies as a Chemical Tool to Probe Immune Molecular Recognition
共价结合抗体作为探测免疫分子识别的化学工具
- 批准号:
565778-2021 - 财政年份:2021
- 资助金额:
$ 15.33万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Master's
Establishment of a novel serum diagnosis method for flaviviruses based on binding profiles of anti-flavivirus antibodies
基于抗黄病毒抗体结合谱建立黄病毒新型血清诊断方法
- 批准号:
20J22269 - 财政年份:2020
- 资助金额:
$ 15.33万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of Antigen Glycosylation in Mucin Binding by Monoclonal Antibodies
抗原糖基化在单克隆抗体粘蛋白结合中的作用
- 批准号:
10045898 - 财政年份:2020
- 资助金额:
$ 15.33万 - 项目类别:
Do anti-DNA antibodies play a role in the pathogenesis of systemic lupus erythematosus by binding/entering live cells?
抗 DNA 抗体是否通过结合/进入活细胞在系统性红斑狼疮的发病机制中发挥作用?
- 批准号:
16K08929 - 财政年份:2016
- 资助金额:
$ 15.33万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
N-Terminally fluorescent-labeled antibodies that show fluorescence change upon antigen-binding
N 末端荧光标记抗体,在抗原结合时显示荧光变化
- 批准号:
15K13739 - 财政年份:2015
- 资助金额:
$ 15.33万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
(i) Identification of single-molecule protein complexes involved in cellular transport of prosthetic groups (Moco and heme) (ii) Generation of monoclonal antibodies directed against protein motifs involved in binding prosthetic groups
(i) 鉴定参与假体基团(Moco 和血红素)细胞运输的单分子蛋白复合物 (ii) 生成针对参与结合假体基团的蛋白基序的单克隆抗体
- 批准号:
226653713 - 财政年份:2012
- 资助金额:
$ 15.33万 - 项目类别:
Research Units














{{item.name}}会员




